Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Sell
40
BLND Quote, Financials, Valuation and Earnings
Last price:
$3.54
Seasonality move
:
-25.61%
Day range:
$3.43 - $3.58
52-week range:
$2.08 - $5.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.39x
P/B ratio:
--
Volume:
2M
Avg. volume:
3.9M
1-year change:
8.86%
Market cap:
$893.2M
Revenue:
$162M
EPS (TTM):
-$0.24
Analysts' Opinion
-
Consensus RatingBlend Labs has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.14, Blend Labs has an estimated upside of 49.47% from its current price of $3.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.50 representing 100% downside risk from its current price of $3.44.
Fair Value
-
According to the consensus of 5 analysts, Blend Labs has 49.47% upside to fair value with a price target of $5.14 per share.
BLND vs. S&P 500
-
Over the past 5 trading days, Blend Labs has underperformed the S&P 500 by -7.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Blend Labs does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Blend Labs has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Blend Labs reported revenues of $41.4M.
Earnings Growth
-
Blend Labs has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Blend Labs reported earnings per share of -$0.03.
Enterprise value:
847.1M
EV / Invested capital:
-212.79x
Price / LTM sales:
5.39x
EV / EBIT:
--
EV / Revenue:
5.23x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-37.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$90.5M
Return On Assets:
-25.91%
Net Income Margin (TTM):
-30.62%
Return On Equity:
-79.84%
Return On Invested Capital:
-42.19%
Operating Margin:
-4.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $235.2M | $156.8M | $162M | $36.1M | $41.4M | |
| Gross Profit | $89.7M | $81.1M | $90.5M | $19.7M | $24.7M | |
| Operating Income | -$281.2M | -$131.3M | -$42.1M | -$21.2M | -$1.7M | |
| EBITDA | -$726.8M | -$143.2M | -$31.7M | -$21.9M | -- | |
| Diluted EPS | -$3.30 | -$0.77 | -$0.24 | -$0.13 | -$0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $186.1M | $613M | $396.1M | $169.8M | $135.2M | |
| Total Assets | $215.7M | $1.1B | $432.8M | $206.1M | $178M | |
| Current Liabilities | $35M | $60M | $35.5M | $31.6M | $38.9M | |
| Total Liabilities | $52.4M | $301.9M | $268.8M | $179.1M | $182M | |
| Total Equity | $163.3M | $810.6M | $163.9M | $26.9M | -$4M | |
| Total Debt | -- | $213.8M | $216.8M | $138.3M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$190.4M | -$127.6M | -$13M | -$20.7M | -$4.6M | |
| Cash From Investing | $99.4M | $127.3M | $45.4M | $53.2M | -$1.9M | |
| Cash From Financing | $2.2M | -$91M | -$21.1M | -$86.1M | -$6.3M | |
| Free Cash Flow | -$192.5M | -$128.2M | -$22.9M | -$20.8M | -$7.2M | |
BLND
Sector
Market Cap
$893.2M
$87.5M
Price % of 52-Week High
62.26%
60.21%
Dividend Yield
0%
0%
Shareholder Yield
--
0.8%
1-Year Price Total Return
8.86%
-16.45%
Beta (5-Year)
--
0.910
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.59
200-day SMA
Sell
Level
$3.65
Bollinger Bands (100)
Sell
Level
3.44 - 4.72
Chaikin Money Flow
Sell
Level
-61.2M
20-day SMA
Buy
Level
$3.41
Relative Strength Index (RSI14)
Sell
Level
45.78
ADX Line
Buy
Level
15.96
Williams %R
Neutral
Level
-51.8072
50-day SMA
Sell
Level
$3.64
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-124.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.428)
Sell
CA Score
(Annual)
Level (-4.1915)
Buy
Beneish M-Score
(Annual)
Level (-3.3313)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (6.1914)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
Stock Forecast FAQ
In the current month, BLND has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BLND average analyst price target in the past 3 months is $5.14.
-
Where Will Blend Labs Stock Be In 1 Year?
According to analysts, the consensus estimate is that Blend Labs share price will rise to $5.14 per share over the next 12 months.
-
What Do Analysts Say About Blend Labs?
Analysts are divided on their view about Blend Labs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Blend Labs is a Sell and believe this share price will drop from its current level to $3.50.
-
What Is Blend Labs's Price Target?
The price target for Blend Labs over the next 1-year time period is forecast to be $5.14 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BLND A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Blend Labs is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BLND?
You can purchase shares of Blend Labs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Blend Labs shares.
-
What Is The Blend Labs Share Price Today?
Blend Labs was last trading at $3.54 per share. This represents the most recent stock quote for Blend Labs. Yesterday, Blend Labs closed at $3.44 per share.
-
How To Buy Blend Labs Stock Online?
In order to purchase Blend Labs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Signet Jewelers Stock Go Up So Much?
Signet Jewelers (NYSE:SIG) is the largest diamond retailer in the…
Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
69
CNXC alert for Mar 28
Concentrix [CNXC] is down 13.44% over the past day.
Buy
74
SLNO alert for Mar 28
Soleno Therapeutics [SLNO] is up 5.58% over the past day.
Buy
51
CAR alert for Mar 28
Avis Budget Group [CAR] is down 0.93% over the past day.
